BDBM336123 US9738676, WS2009/106419, Expl. 15

SMILES CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C(=O)N2CCOCC2)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2[C@H](SCCOc3cc(ccc3CO)C(=O)Nc3c(Cl)cncc3Cl)C(=O)O[C@]12C)OC

InChI Key InChIKey=ODLXGNROWIUOTC-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 336123   

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Human)
Basilea Pharmaceutica

US Patent
LigandPNGBDBM336123(US9738676, WS2009/106419, Expl. 15)
Affinity DataIC50: 71nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent